Three independent discounted-cash-flow-style models value Aktis Oncology, Inc. Common stock every trading day. 0 of 3 currently price AKTS above its market price.
| Free Cash Flow model | $-62.18 |
| Excess Profit model | $-102.15 |
| Residual Earnings model | $-0.22 |
| Dividend Discount model | — |
| Piotroski F-Score | 4 / 9 |
| Return on invested capital | +10.0% |
| Net debt / EBITDA | — |
| Gross margin | -2.5% |
| Revenue CAGR | +60.5% |
| Cash conversion | — |
| Dividend yield | — |
| Buyback yield | -40.0% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open AKTS in StockKitty